Navigation Links
Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
Date:5/28/2013

SEATTLE, Wash., May 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a Clinical Trial Application (CTA) with European regulators to initiate clinical trials evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program. The lead indication for OMS721 will be atypical hemolytic uremic syndrome (aHUS), a rare but life-threatening form of thrombotic microangiopathy (TMA). Assuming positive regulatory review of its CTA, Omeros plans to initiate a Phase 1 clinical trial evaluating OMS721 early next quarter.

The Phase 1 clinical trial will be a placebo-controlled, double-blind, single-ascending-dose study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of OMS721 administered subcutaneously in healthy subjects. Immediately following this study, Omeros plans to advance OMS721 into a Phase 2 clinical trial in aHUS patients.

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein involved in activation of the complement system – an important component of the immune system. The complement system plays a role in the inflammatory response to tissue damage or microbial infection. OMS721 selectively inhibits MASP-2, blocking the lectin pathway of the complement system while leaving intact the classical pathway, which represents the acquired immune response to infection. Soliris® (eculizumab), the only approved complement-targeting antibody on the market and the only currently approved therapy for aHUS, inhibits microbial killing by the classical pathway, increasing the risk of infection for the patient. By targeting only the lectin pathway and leaving the classical pathway intact, OMS721 should not have this increased infect
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Corporation Reports First Quarter 2013 Financial Results
2. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
3. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
4. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
5. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
6. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
7. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
8. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
9. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
10. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
11. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
(Date:12/15/2014)... Washington State are not the only ... Oregon , Alaska , and ... 2014 elections. Photo - http://photos.prnewswire.com/prnh/20141212/164152 ... The benefits of legalizing cannabis are manifold. There are the ... revenue for state and local governments, in addition to reduced ...
(Date:12/15/2014)... SAN MARCOS, Texas , Dec. 15, 2014 /PRNewswire/ ... quantum dot manufacturer Quantum Materials Corp (OTCQB:QTMM), ... Rice Center for Quantum Materials (RCQM) on December 16th, ... the exploration of exotic nanomaterials in attracting top faculty ... to Rice to collaborate on research. ...
Breaking Medicine Technology:Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
... Agennix Incorporated today announced,the publication of final ... alfa in patients who had failed previous treatment ... from the study,which were reported in the July ... 1), demonstrate that talactoferrin is active in RCC, ...
... Evaluate Preventive Treatment of ... Vulnerable Plaques, ROTTERDAM, Netherlands and DOYLESTOWN, Pa., June ... W. Serruys,successfully placed a vProtect(TM) Luminal Shield in the ... at Erasmus Medical,Center in Rotterdam. This case marks the ...
Cached Medicine Technology:Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 2Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 3Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 4Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 5Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 2Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... accurate method of assessing people at risk from cardiovascular disease ... those at risk among black and minority ethnic groups. ... most at risk of developing CVD for the first time, ... and other clinical conditions such as family history of heart ...
... 24 The Rehabilitation Institute,of Chicago and MediCom ... on Pain July 18th and 19th. The meeting ... of Northwestern University in Chicago., This year, ... Opioid,Management." The scientific agenda will focus on the ...
... Food Snacks Contain Ingredients Medically Proven to Reduce ... Impact of Diagnosed ... In response to increasing,demand for convenient, tasty, satisfying foods ... WatchDog Nutrition(TM) today announced,availability of its snack bars in ...
... BETHLEHEM, Pa., June 24 At this year,s ... Inc. and its MIKE AND,IKE(R) Candy Brand presented ... the first in a multi-year commitment to this ... MIKE AND IKE(R) Lemonade Blends(TM) kicks off Just ...
... June 24 Go Healthy, Inc. (Pink,Sheets: GOHE) announced ... AIM Marketing, based in Myakka, Florida. Under the terms ... number of marketing and,sales related services designed to bring ... clients. Some specifics outlined in the agreement,are as follows:, ...
... June 24 /PRNewswire-FirstCall/ - Beeston Enterprises Ltd.,("Beeston" or ... on its Bluff Lake property that it holds ... "CDO"). The property is,located on the northern border ... continues to delineate significant alkalic copper-gold deposits., ...
Cached Medicine News:Health News:New cardiovascular score developed to improve heart attack and stroke detection 2Health News:3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc. 2Health News:Heart Disease and Diabetes Finally Meet Their Match With Delicious New Snack Bars From WatchDog Nutrition(TM) 2Health News:MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alex's Lemonade Stand Foundation 2Health News:Go Healthy Signs Marketing Contract with AIM Marketing 2Health News:Beeston completes drilling on Bluff Lake property, 100 Mile House 2
A straight suture punch with 2.5 mm needle and 2/0 to #1 monofilament suture....
Leg holder for arthroscopy....
... High-Performance Pump in Arthroscopy. Ease of use ... that make the 10k Fluid System unique. ... for Arthroscopy, maintains intra-articular pressure, while providing ... Fluid System, when used for Laparoscopy, provides ...
The Sony DSR20-MD Grade Digital Video Player/Recorder represents a giant leap in digital technology. , ,This equipment is intended to be used by physicians who teach or present medical techniques...
Medicine Products: